XTALPI (02228) subsidiary LCC TECHNOLOGIES enters into a drug discovery collaboration agreement with Stanford University

XTALPI (02228) announces that its wholly-owned subsidiary, LCC Technologies Ltd. (LCC Technologies), and the Board of Trustees of Stanford University have entered into a drug discovery collaboration agreement. The collaboration combines Stanford University's disease biology research with LCC Technologies' automated and AI-driven small molecule drug discovery platform to accelerate and advance the development of new drugs. Under the collaboration, novel biological insights derived from Stanford University's disease biology research will be evaluated for their potential to be developed into small molecule therapeutics using LCC Technologies' proprietary PACE drug discovery platform. PACE integrates fragment-based drug discovery, AI-driven computational design, automated synthesis, and iterative design-make-test-analyze (DMTA) cycles. The collaboration is not limited to a specific disease area. Under the collaboration, principal investigators at Stanford University will have the opportunity to propose projects based on their research to a joint steering committee established by Stanford University and LCC Technologies. The steering committee will evaluate proposed projects based on scientific merit, feasibility, and potential therapeutic impact, and select the most promising projects for further development to advance to clinical evaluation and beyond. The Board believes that the collaboration consolidates the Group's position in the field of AI + automation-driven drug discovery and provides the Group, through LCC Technologies, with opportunities to participate in early-stage collaborative projects, with the aim of translating promising biological insights into potential small molecule therapeutics.